Biohaven Ltd. (BHVN)
NYSE · Healthcare · Biotechnology
$12.97+0.78%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.0B
- 52-week range
- $7.48 – $18.57
- 52-week change
- −14.31%
- EPS (trailing)
- −$4.60
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Net income
- −$739M
- Diluted EPS
- −$6.86
- Free cash flow
- −$610M
From the company’s annual report on SEC EDGAR.
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
Headquarters: New Haven, United States · 274 employees · biohaven.com